Nov 18, 2024 7:00 am EST Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Nov 14, 2024 7:00 am EST Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Nov 7, 2024 4:01 pm EST Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights